116 completed, 31 terminated, 25 active not recruiting, 24 recruiting. 95 Phase 1, 91 Phase 2, 18 Not applicable, 7 Early Phase 1, 6 Phase 3.
Follow Ependymoma: new trials by email Literature Review of Ependymoma trials Research Report on Ependymoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PEP-CMV + Nivolumab for Newly Diagnosed Diffuse Midline Glioma/High-grade Glioma and Recurrent Diffuse Midline Glioma/High-grade Glioma, Medulloblastoma, and Ependymoma PEP-CMV vaccine, Tetanus booster, Nivolumab - Diffuse Midline Glioma, Diffuse Midline High-grade Glioma | Phase 1 / Phase 2 | Suspended | Washington University School of Medicine | 68 | 2026-09-30 | 2026-09-11 |
| Pharmacoscopy for Patients With Refractory Primary Brain Tumors Pharmacoscopy 1.0 - Brain (Nervous System) Cancers, Glioblastoma | Phase 2 | Recruiting | University of Zurich | 40 | 2026-09-11 | 2026-09-21 |
| B7-H3.CD28Z.CART in CNS Neoplasms B7-H3.CD28Z.CART, Fludarabine, Cyclophosphamide - Central Nervous System Neoplasms, Brain Tumor | Phase 1 | Recruiting | Robbie Majzner | 70 | 2026-09-01 | 2026-09-03 |
| A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma Cemiplimab, Cemiplimab+Fianlimab Fixed Dose Combination (FDC) - High-Grade Glioma (HGG), Posterior Fossa-A Ependymoma | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 120 | 2026-08-31 | 2026-05-05 |
| Determine Maximum Tolerated Dose, Safety, and Tolerability of Rhenium (186Re) in Pediatric Recurrent, Refractory or Progressive Ependymoma and High-Grade Glioma Rhenium-186 Nanoliposome - Ependymoma, High Grade Gliomas | Phase 1 | Recruiting | Cerenome | 56 | 2026-08-01 | 2026-09-11 |
| Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 200 | 2026-07-18 | 2026-07-20 |
| Selumetinib for NF2-Related Schwannomatosis Selumetinib - Neurofibromatosis Type 2, NF2 | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 20 | 2026-07-15 | 2026-07-16 |
| AI-Assisted MRI Molecular Subtyping in Pediatric Brain Tumors Pediatric Brain Tumors, Glioma | Not yet recruiting | Huashan Hospital | 1400 | 2026-07-15 | 2026-07-23 | |
| Activated Autologous T Cells Against Glioma Cancer Stem Cell Antigens for Patients With Recurrent Glioblastoma Activated T cells - Recurrent Glioblastoma | Phase 1 | Withdrawn | Jeremy Rudnick, M.D | 2026-06-01 | 2025-10-22 | |
| Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being Group Self-Management Sessions, Educational Materials Only - Brain Cancer | Not applicable | Not yet recruiting | University of Colorado, Denver | 64 | 2026-06-01 | 2026-06-05 |
| Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors DNX-2401 - High Grade Glioma, Ependymoma | Phase 2 | Recruiting | Clinica Universidad de Navarra, Universidad de Navarra | 39 | 2026-05-12 | 2026-05-27 |
| Safety and Efficacy of Vertebral Body-Sparing Craniospinal Irradiation With Proton Therapy in Pediatric Tumors Vertebral Body-Sparing Craniospinal Proton Irradiation - Pediatric Central Nervous System Tumors, Medulloblastoma | Not yet recruiting | Ruijin Hospital | 38 | 2026-04-30 | 2026-05-15 | |
| Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma exHSC, Nivolumab, Resection or biopsy - Recurrent High-grade Glioma, Grade III Astrocytoma | Phase 1 | Active not recruiting | University of Florida | 12 | 2025-07-25 | 2026-09-23 |
| Integrated Analysis of Therapy Response and Resistence in Embryonal Tumors and Gliomas Tissue, blood, cerebrospinal-spinal fluid - Glioma, Malignant, Embryonal Tumor | Not yet recruiting | University Hospital Regensburg | 72 | 2025-05-01 | 2025-03-25 | |
| The Use of 5-ALA in Paediatric Patients With High Grade Brain Tumours 5-ALA (Gliolan) - Brain Tumor | Phase 2 | Not yet recruiting | University College, London | 80 | 2025-03-25 | 2025-03-27 |
| A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer Cobolimab, Dostarlimab - Melanoma, Hodgkin Lymphoma | Phase 1 / Phase 2 | Active not recruiting | GlaxoSmithKline | 83 | 2025-03-06 | 2025-11-12 |
| Systemic Biomarkers to Predict Radiation-Induced Neurocognitive Decline Brain Tumors, Medulloblastoma | Recruiting | Tata Memorial Centre | 200 | 2025-02-11 | 2025-04-11 | |
| Axitinib and Oral Metronomic Etoposide for Pediatric Children and AYA Refractory/Relapsing Medulloblastoma and Ependymoma administration of axitinib in combination with etoposide - Medulloblastoma, Ependymoma | Phase 1 / Phase 2 | Not yet recruiting | Assistance Publique Hopitaux De Marseille | 40 | 2024-10-01 | 2024-07-03 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) Multi-tumor antigen specific cytotoxic T lymphocytes (TSA-T) directed against proteogenomically determined personalized tumor-specific antigens (TSA), Group A Standard-of-Care Backbone Therapy, Group B Salvage Backbone Therapy - Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS | Phase 1 | Recruiting | Children's National Research Institute | 12 | 2024-09-20 | 2026-10-13 |
Showing 20 of 225. Sign in to see all of them.
Glioma (143) · Brain Neoplasms (122) · Astrocytoma (114) · Glioblastoma (113) · Medulloblastoma (112) · Oligodendroglioma (101) · Central Nervous System Neoplasms (85) · Gliosarcoma (82) · Neuroectodermal Tumors, Primitive (59) · Meningioma (51) · Glioma, Subependymal (45) · Pinealoma (41) · Rhabdoid Tumor (36) · Choroid Plexus Neoplasms (29)
Neoplasms by Histologic Type (224) · Neoplasms, Glandular and Epithelial (224) · Neoplasms, Nerve Tissue (224) · Neuroectodermal Tumors (221) · Neoplasms, Neuroepithelial (217) · Neoplasms, Germ Cell and Embryonal (209) · Neoplasms (206) · Neoplasms by Site (181) · Nervous System Diseases (173) · Nervous System Neoplasms (172) · Central Nervous System Diseases (141) · Brain Diseases (139) · Central Nervous System Neoplasms (88) · Glioma (82) · Neuroectodermal Tumors, Primitive (67)
Temozolomide (27) · Magnetic Resonance Spectroscopy (19) · Etoposide (14) · Cyclophosphamide (13) · Radiotherapy (12) · Bevacizumab (10) · Filgrastim (10) · Carboplatin (9) · Biopsy (8) · Cisplatin (7) · Carmustine (6) · Phantoms, Imaging (6) · Specimen Handling (6) · Thiotepa (6) · X-Rays (6)
National Cancer Institute (NCI) (33) · M.D. Anderson Cancer Center (8) · City of Hope Medical Center (7) · Wake Forest University Health Sciences (7) · Case Comprehensive Cancer Center (6) · Duke University (6) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6) · St. Jude Children's Research Hospital (6) · Children's Oncology Group (5) · Memorial Sloan Kettering Cancer Center (5) · European Organisation for Research and Treatment of Cancer - EORTC (4) · National Institutes of Health Clinical Center (CC) (4) · Pediatric Brain Tumor Consortium (4) · Beijing Tiantan Hospital (3) · NYU Langone Health (3)
United States (183) · Canada (16) · Puerto Rico (14) · Australia (11) · France (10) · Spain (8) · United Kingdom (8) · Italy (7) · Switzerland (7) · Germany (6) · Netherlands (5) · China (4) · Denmark (4) · Austria (3) · Belgium (3)
Darell D. Bigner, MD, PhD (3) · Edward G. Shaw, MD (3) · Katherine E Warren, M.D. (3) · David Sandberg, MD (2) · Jana Portnow, MD (2) · Jeffry Alger, PhD (2) · Jing Wu, M.D. (2) · Kim Kramer, MD (2) · Rebecca Ronsley, MD (2) · Stefan Rutkowski, Prof. (2) · Stewart Goldman, MD (2) · Stuart A. Grossman, MD (2) · Thomas Kaley, MD (2)
PMID 31401903, PMID 34171339, PMID 11410496, PMID 11835236, PMID 12721262, PMID 16549835, PMID 16817692, PMID 16914578, PMID 17264335, PMID 18048828, PMID 18056189, PMID 18447671, PMID 18470481, PMID 18543042, PMID 18824712, PMID 18850068, PMID 19248046, PMID 19768386, PMID 21850464, PMID 22291006, PMID 22480131, PMID 23243055, PMID 23380277, PMID 23388559, PMID 23956241, PMID 24309981, PMID 24553142, PMID 25113840, PMID 27020837, PMID 27269943, PMID 28371832, PMID 28570730, PMID 30118397, PMID 30730781, PMID 30825962, PMID 30883662, PMID 31774710, PMID 31876107, PMID 32373649, PMID 32719487, PMID 33025730, PMID 33235996, PMID 33591402, PMID 33838625, PMID 33842889, PMID 34168987, PMID 34253928, PMID 34486544, PMID 35022322, PMID 35157764
U10CA180886 (14), UM1CA081457 (8), P30CA033572 (5), P30CA016672 (3), P30CA043703 (3), U10CA081851 (3), P30CA006973 (2), P30CA008748 (2), P30CA022453 (2), U01CA062399 (2), U10CA098543 (2), 2009 (1), 2016 (1), 2019 (1), 2023 (1)